Diagnostic Value of Neuron Specific Enolase for Malignant Pleural Effusion: A Meta-Analysis_Chinese Journal of Evidence-Based Medicine

Authors：

 JIANGYAO-Wen ¹ , LIUPeng ¹ , LINGYUN-Fei ² ,  HUHai ¹

1. Department of Emergency, West China Hospital, Sichuan University, Chengdu 610041, China;
2. West China School of Medicine, Sichuan University, Chengdu 610041, China;

Corresponding?author：

HUHai, Email: hhtg2014@126.com

Keywords：

Neuron specific enolase(NSE); Pleural effusion; Diagnosis; Meta-analysis

DOI：

10.7507/1672-2531.20140099

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the diagnostic value of neuron specific enolase (NSE) for malignant pleural effusion. Methods We comprehensively searched databases including The Cochrane Library (Issue 1, 2012), EMbase, MEDLINE, CBM, CNKI, WanFang Data and VIP from inception to January 2012 to collect studies about the diagnostic value of NSE for malignant pleural effusion. Literature screening according to the inclusion and exclusion criteria, data extraction and methodological quality assessment were completed by two reviewers independently. Then Meta-DiSc software (version 1.4) was used for pooling analysis. Results A total of 12 studies were finally included. The results of meta-analysis showed that the value of pooled specificity, sensitivity, positive likelihood radio, negative likelihood radio and diagnostic odds ratio (DOR) were 0.79 (0.76 to 0.84), 0.55 (0.51 to 0.59), 3.2 (1.94 to 5.29), 0.58 (0.45 to 0.74), 7.56 (3.74 to 15.30), respectively; and the area under SROC curve (AUC) was 0.813 1. Conclusion Using NSE as a maker to diagnose malignant pleural effusion is of certain clinical value, which is used to differentiate benign and malignant pleural effusion.

Citation： JIANGYAO-Wen, LIUPeng, LINGYUN-Fei, HUHai. Diagnostic Value of Neuron Specific Enolase for Malignant Pleural Effusion: A Meta-Analysis. Chinese Journal of Evidence-Based Medicine, 2014, 14(5): 598-603. doi: 10.7507/1672-2531.20140099 Copy

1.	Chernow B, Sahn SA. Carcinomatous involvement of the pleura:an analysis of 96 patients. Am J Med, 1977, 63(5):695-702.
2.	Prakash BS, Reiman HM. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion:analysis of 414 cases. Mayo Clin Proc, 1985, 60(2):158-164.
3.	Johnston WW. The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer, 1985, 56(4):905-909.
4.	Menard O, Dousset B, Jacob C, et al. Improvement of the diagnosis of the cause of pleural effusion in patients with lung cancer by simultaneous quantification of carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) pleural levels. Eur J Cancer, 1993, 29(13):1806-1809.
5.	Filiz K, Zeynep T, Abdurrahman C, et al. Diagnostic usefulness of tumour marker levels in pleural effusions of malignant and benign origin. Clinica Chimica Acta, 2000, 300(1):43-55.
6.	Ghayumi SM, Mehrabi S, Doroudchi M, et al. Diagnostic value of tumor markers for differentiating malignant and benign pleural effusions of Iranian patients. Pathol Oncol Res, 2005, 11(4):236-241.
7.	盛家和, 肖偉強, 許青霞, 等.癌性胸水患者血清和胸水中水溶性細胞角蛋白19片段、癌胚抗原和神經元特異性烯醇化酶檢測.鄭州大學學報(醫學版), 2008, 43(4):768-771.
8.	倪寧, 李韶英.多種腫瘤標志物聯合檢測對胸腔積液鑒別診斷的意義.遼寧醫學雜志, 2004, 18(6):308-309.
9.	王群慧, 張樹才, 古淑香, 等.檢測糖鏈抗原CA242對惡性胸液的診斷價值.中國肺癌雜志, 2002, 5(1):44-47.
10.	端木和運, 曹惠娟.聯合檢測CA125、CA153、CEA、NSE和SF鑒別結核性與癌性積液.江蘇醫藥, 2011, 37(23):2778-2780.
11.	黃河, 熊盛道, 張家洪, 等.黏蛋白類糖鏈抗原CA724與腫瘤標志物癌胚抗原、神經元特異度烯醇化酶、細胞角質蛋白19的可溶片段聯合檢測對良惡性胸腔積液鑒別診斷的意義.臨床薈萃, 2010, 25(12):1075-1078.
12.	唐華平, 李雙保, 張明泳, 等.三項腫瘤標志物聯檢對胸腔積液的鑒別診斷價值.齊魯醫學雜志, 2002, 17(1):35-36.
13.	楊桐樹, 李文輝, 孫喜文, 等.血清五種腫瘤標志物聯合檢測在肺癌診斷中的意義.實用腫瘤學雜志, 2010, 24(3):243-246.
14.	陳連周, 鄭璐, 李雯, 等.腫瘤標志物檢測在良惡性胸腔積液鑒別診斷的應用.中國熱帶醫學, 2008, 8(10):1709-1710.
15.	Korczyns P, Krenke R, Safianowska A, et al. Diagnostic utility of pleural fluid and serum markers in differentiation between malignant and non-malignant pleural effusions. Eur J Med Res, 2009, 14(Suppl 4):128-133.
16.	Romero S, Izquierdo M, Mauri M, et al. Diagnostic usefulness of neurospecific enolase determination in pleural fluid. Med Clin (Barc), 1989, 93(15):568-571.
17.	刁驤, 艾昌林, 秦莉, 等譯. QUADAS的制定:用于系統評價診斷性研究質量的工具.中國循證醫學雜志, 2007, (04):296-306.
18.	李盈, 顧懷婷. 《中國循證醫學雜志》發表系統評價/Meta分析的文獻計量分析.中國循證醫學雜志, 2012, 12(10):1279-1282.
19.	Penny F, Marie E, Weswood A, 等. QUADAS評價:一種用于診斷性研究的質量評價工具(修訂版).中國循證醫學雜志, 2007, 7(7): 531-536.
20.	鄧可剛.診斷性研究的檢索資源與檢索方法.中國循證醫學雜志, 2007, 7(4):307-310.
21.	劉關鍵, 吳泰相.診斷性試驗的Meta分析-SROC曲線法介紹.中國循證醫學雜志, 2003, 3(1):41-44.
22.	馬清光, 鄧嘉佳, 喬英, 等.國內癌胚抗原檢測診斷非小細胞肺癌的系統評價.中國循證醫學雜志, 2011, 11(10):1140-1143.

1. Chernow B, Sahn SA. Carcinomatous involvement of the pleura:an analysis of 96 patients. Am J Med, 1977, 63(5):695-702.
2. Prakash BS, Reiman HM. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion:analysis of 414 cases. Mayo Clin Proc, 1985, 60(2):158-164.
3. Johnston WW. The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer, 1985, 56(4):905-909.
4. Menard O, Dousset B, Jacob C, et al. Improvement of the diagnosis of the cause of pleural effusion in patients with lung cancer by simultaneous quantification of carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) pleural levels. Eur J Cancer, 1993, 29(13):1806-1809.
5. Filiz K, Zeynep T, Abdurrahman C, et al. Diagnostic usefulness of tumour marker levels in pleural effusions of malignant and benign origin. Clinica Chimica Acta, 2000, 300(1):43-55.
6. Ghayumi SM, Mehrabi S, Doroudchi M, et al. Diagnostic value of tumor markers for differentiating malignant and benign pleural effusions of Iranian patients. Pathol Oncol Res, 2005, 11(4):236-241.
7. 盛家和, 肖偉強, 許青霞, 等.癌性胸水患者血清和胸水中水溶性細胞角蛋白19片段、癌胚抗原和神經元特異性烯醇化酶檢測.鄭州大學學報(醫學版), 2008, 43(4):768-771.
8. 倪寧, 李韶英.多種腫瘤標志物聯合檢測對胸腔積液鑒別診斷的意義.遼寧醫學雜志, 2004, 18(6):308-309.
9. 王群慧, 張樹才, 古淑香, 等.檢測糖鏈抗原CA242對惡性胸液的診斷價值.中國肺癌雜志, 2002, 5(1):44-47.
10. 端木和運, 曹惠娟.聯合檢測CA125、CA153、CEA、NSE和SF鑒別結核性與癌性積液.江蘇醫藥, 2011, 37(23):2778-2780.
11. 黃河, 熊盛道, 張家洪, 等.黏蛋白類糖鏈抗原CA724與腫瘤標志物癌胚抗原、神經元特異度烯醇化酶、細胞角質蛋白19的可溶片段聯合檢測對良惡性胸腔積液鑒別診斷的意義.臨床薈萃, 2010, 25(12):1075-1078.
12. 唐華平, 李雙保, 張明泳, 等.三項腫瘤標志物聯檢對胸腔積液的鑒別診斷價值.齊魯醫學雜志, 2002, 17(1):35-36.
13. 楊桐樹, 李文輝, 孫喜文, 等.血清五種腫瘤標志物聯合檢測在肺癌診斷中的意義.實用腫瘤學雜志, 2010, 24(3):243-246.
14. 陳連周, 鄭璐, 李雯, 等.腫瘤標志物檢測在良惡性胸腔積液鑒別診斷的應用.中國熱帶醫學, 2008, 8(10):1709-1710.
15. Korczyns P, Krenke R, Safianowska A, et al. Diagnostic utility of pleural fluid and serum markers in differentiation between malignant and non-malignant pleural effusions. Eur J Med Res, 2009, 14(Suppl 4):128-133.
16. Romero S, Izquierdo M, Mauri M, et al. Diagnostic usefulness of neurospecific enolase determination in pleural fluid. Med Clin (Barc), 1989, 93(15):568-571.
17. 刁驤, 艾昌林, 秦莉, 等譯. QUADAS的制定:用于系統評價診斷性研究質量的工具.中國循證醫學雜志, 2007, (04):296-306.
18. 李盈, 顧懷婷. 《中國循證醫學雜志》發表系統評價/Meta分析的文獻計量分析.中國循證醫學雜志, 2012, 12(10):1279-1282.
19. Penny F, Marie E, Weswood A, 等. QUADAS評價:一種用于診斷性研究的質量評價工具(修訂版).中國循證醫學雜志, 2007, 7(7): 531-536.
20. 鄧可剛.診斷性研究的檢索資源與檢索方法.中國循證醫學雜志, 2007, 7(4):307-310.
21. 劉關鍵, 吳泰相.診斷性試驗的Meta分析-SROC曲線法介紹.中國循證醫學雜志, 2003, 3(1):41-44.
22. 馬清光, 鄧嘉佳, 喬英, 等.國內癌胚抗原檢測診斷非小細胞肺癌的系統評價.中國循證醫學雜志, 2011, 11(10):1140-1143.

Chinese Journal of Evidence-Based Medicine

Diagnostic Value of Neuron Specific Enolase for Malignant Pleural Effusion: A Meta-Analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content